Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wyndham Wilson

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Frontiers in Pediatrics|March 16, 2017
DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in PresentationVictoria R Dimitriades, Vincent Devlin, Stefania Pittaluga, et al.
Clinical Nuclear Medicine|August 22, 2014
A pilot study of the value of 18F-fluoro-deoxy-thymidine PET/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapyEsther Mena, Maria Liza Lindenberg, Baris I Turkbey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignanciesMatthias Grube, Katayoun Rezvani, Adrian Wiestner, et al.
Cytometry. Part B, Clinical Cytometry|April 24, 2008
Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemiaEjaz Ahmad, Seth M Steinberg, Lynn Goldin, et al.
Hepatology Communications|February 16, 2019
Development of Hepatic Steatosis After Chemotherapy for Non-Hodgkin LymphomaGil Ben-Yakov, Hawwa Alao, John P Haydek, et al.
Nature Reviews. Clinical Oncology|December 30, 2016
The landscape of new drugs in lymphomaAnas Younes, Stephen Ansell, Nathan Fowler, et al.
British Journal of Haematology|May 4, 2021
Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinibSriram Balasubramanian, Songbai Wang, Christopher Major, et al.
Blood Advances|March 4, 2026
A phase 1 trial of romidepsin, azacitidine, dexamethasone and lenalidomide in relapsed or refractory T-cell lymphomaMax J Gordon, Milos D Miljkovic, Paige Milhon, et al.
American Journal of Hematology|January 25, 2006
Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS)V Koneti Rao, Jorge A Carrasquillo, Janet K Dale, et al.
Ejhaem|December 5, 2022
Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non-germinal centre B-cell-like diffuse large B-cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trialJun Zhu, Xiaonan Hong, Yu Qin Song, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Frontiers in Pediatrics|March 16, 2017
DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in PresentationVictoria R Dimitriades, Vincent Devlin, Stefania Pittaluga, et al.
Clinical Nuclear Medicine|August 22, 2014
A pilot study of the value of 18F-fluoro-deoxy-thymidine PET/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapyEsther Mena, Maria Liza Lindenberg, Baris I Turkbey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignanciesMatthias Grube, Katayoun Rezvani, Adrian Wiestner, et al.
Cytometry. Part B, Clinical Cytometry|April 24, 2008
Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemiaEjaz Ahmad, Seth M Steinberg, Lynn Goldin, et al.
Hepatology Communications|February 16, 2019
Development of Hepatic Steatosis After Chemotherapy for Non-Hodgkin LymphomaGil Ben-Yakov, Hawwa Alao, John P Haydek, et al.
Nature Reviews. Clinical Oncology|December 30, 2016
The landscape of new drugs in lymphomaAnas Younes, Stephen Ansell, Nathan Fowler, et al.
British Journal of Haematology|May 4, 2021
Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinibSriram Balasubramanian, Songbai Wang, Christopher Major, et al.
Blood Advances|March 4, 2026
A phase 1 trial of romidepsin, azacitidine, dexamethasone and lenalidomide in relapsed or refractory T-cell lymphomaMax J Gordon, Milos D Miljkovic, Paige Milhon, et al.
American Journal of Hematology|January 25, 2006
Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS)V Koneti Rao, Jorge A Carrasquillo, Janet K Dale, et al.
Ejhaem|December 5, 2022
Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non-germinal centre B-cell-like diffuse large B-cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trialJun Zhu, Xiaonan Hong, Yu Qin Song, et al.
Pageof 5